Programmed death-1 (PD-1) inhibition with pembrolizumab led to durable remission in 31.3% of patients with early acute ...

Schrodinger (SDGR) stock falls as Citi downgrades the company following its decision to halt a clinical development program for a leukemia candidate. Read more here.

Schrödinger is abandoning its CDC7 inhibitor after the therapy was linked to the deaths of two patients in a phase 1 leukemia trial. The biotech had been evaluating the asset, dubbed SGR-2921, in an ...

Amir Fathi, MD, leukemia specialist at Massachusetts General Hospital, discusses the importance of advocacy by both patients ...

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Friday said a third patient has been successfully treated under its phase one trial of its CAR-T cell therapy, HG-CT-1, for relapsed or refractory ...

Researchers sought to determine whether elderly, fit patients with AML would respond to therapy with venetoclax plus modified intensive chemotherapy.

Magrolimab triple therapy falls short of expectations in a study of previously untreated acute myeloid leukemia.

Schrodinger discontinued its study of a potential treatment for acute myeloid leukemia or high-risk myelodysplastic syndromes, citing patient deaths linked to the treatment.

Diagnosis, treatment, response monitoring, and outcome of pediatric acute myeloid leukemia (AML) have made enormous progress during the past decades. Because AML is a rare type of childhood cancer, ...

Stillpoint Mission; kickoff for Walk to End Alzheimer’s; Big Waters fundraiser; Sarasota/Manatee MPO meeting; youth grief ...

Schrödinger said on Thursday it has stopped the development of an experimental drug after the death of two patients with a ...